

June 13, 2019  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 46<sup>th</sup> Stock Acquisition Rights (with Exercise Price Revision Clauses)  
 Issued by way of Third Party Allotment**

TOKYO, Japan, June 13, 2019—Symbio Pharmaceuticals Limited announces the large volume exercise of the 46<sup>th</sup> Stock Acquisition Rights, issued and allotted to EVO FUND on April 25, 2018, during the period from June 12, 2019 to June 13, 2019, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 46 <sup>th</sup> Stock Acquisition Rights
(2)	Number of issued shares from the previous disclosure	1,500,000 Shares
(3)	Number of stock acquisition rights being exercised from the previous disclosure and the ratio to the entire issue	1,500,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 10.00%)
(4)	Number of unexercised stock acquisition rights as of the previous disclosure	3,366,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	1,866,000 Units

(6) Exercise status from the previous disclosure

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
June 12 (Wed.)	500,000	—	154	500,000
June 13 (Thu.)	1,000,000	—	154	1,000,000

※Number of issued shares at the end of the previous month : 91,784,724 shares [of which 75 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45<sup>th</sup> through 47<sup>th</sup> Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.